TP53 and breast cancer: However, Appleyard et al. [47] observed no changes in p53 or survivin levels following combined applications of roscovitine and doxorubicin in a breast cancer xenograft model, suggesting that cell cycle arrest rather than apoptosis is the main mechanism of the enhanced antitumor effect.